Multiple myeloma oncogene 1 (MUM1)/interferon regulatory factor 4 (IRF4) upregulates monokine induced by interferon-γ (MIG) gene expression in B-cell malignancy

Leukemia

Volumn 19, Issue 8, 2005, Pages 1471-1478

  Uranishi, M ^a   Iida, S ^a   Sanda, T ^a   Ishida, T ^a   Tajima, E ^a,b   Ito, M ^b   Komatsu, H ^a   Inagaki, H ^a   Ueda, R ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

B cell; Monokine induced by interferon (MIG); Multiple myeloma oncogene 1(MUM1) interferon regulatory factor 4 (IRF4); Transcriptional regulation

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; FK 506 BINDING PROTEIN; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 4; MONOKINE; NEUTRALIZING ANTIBODY; TRANSCRIPTION FACTOR PU 1; ZINC FINGER PROTEIN;

ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; CELL LINE; CELL PROLIFERATION; CHROMOSOME 14Q; CHROMOSOME 6P; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 6; CORRELATION ANALYSIS; DISEASE COURSE; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; SEQUENCE ANALYSIS; UPREGULATION;

EID: 23744483154     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403833     Document Type: Article

References (35)

1. Iida S, Rao PH, Butler M, Corradini P, Boccadoro M, Klein B et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet 1997; 17: 226-230.
2. Tajima E, Uranishi M, Iida S, Komatsu H, Nitta M, Ueda R. Global real-time quantification/reverse transcription-polymerase chain reaction for detecting proto-oncogenes associated with 14q32 chromosomal translocation in multiple myeloma. Haematologica 2005; 90: 559-562.
3. Matsuyama T, Grossman A, Mittrucker HW, Siderovski DP, Kiefer F, Kawakami T et al. Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE). Nucleic Acids Res 1995; 23: 2127-2136.
4. Yamagata T, Nishida J, Tanaka S, Sakai R, Mitani K, Yoshida M et al. A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. Mol Cell Biol 1996; 16: 1283-1294.
5. Eisenbeis CF, Singh H, Storb U. Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator. Genes Dev 1995; 9: 1377-1387.
6. Mittrucker HW, Matsuyama T, Grossman A, Kundig TM, Potter J, Shahinian A et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 1997; 275: 540-543.
7. Pongubala JM, Atchison ML. PU.1 can participate in an active enhancer complex without its transcriptional activation domain. Proc Natl Acad Sci USA 1997; 94: 127-132.
8. Pernis AB. The role of IRF4 in B and T cell activation and differentiation. J Interferon Cytokine Res 2002; 22: 111-120.
9. Pongubala JM, Nagulapalli S, Klemsz MJ, McKercher SR, Maki RA. Atchison ML. PU.1 recruits a second nuclear factor to a site important for immunoglobulin kappa 3′ enhancer activity. Mol Cell Biol 1992; 12: 368-378.
10. Eisenbeis CF, Singh H, Storb U. PU.1 is a component of a multi-protein complex which binds an essential site in the murine immunoglobulin lambda 2-4 enhancer. Mol Cell Biol 1993; 13: 6452-6461.
11. Himmelmann A, Riva A, Wilson GL, Lucas BP, Thevenin C, Kehrl JH. PU.1/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 promoter to help confer lineage- and stage-specific expression of CD20 in B lymphocytes. Blood 1997; 90: 3984-3995.
12. Tsuboi K, Iida S, Inagaki H, Kato M, Hayami Y, Hanamura I et al. MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia 2000; 14: 449-456.
13. Imaizumi Y, Kohno T, Yamada Y, Ikeda S, Tanaka Y, Tomonaga M et al. Possible involvement of interferon regulatory factor 4 (IRF4) in a clinical subtype of adult T-cell leukemia. Jpn J Cancer Res 2001; 92: 1284-1292.
14. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
15. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
16. Ito M, Iida S, Inagaki H, Tsuboi K, Komatsu H, Yamaguchi M et al. MUM1/IRF4 expression is an unfavorable prognostic factor in B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Jpn J Cancer Res 2002; 93: 685-694.
17. Chang CC, Lorek J, Sabath DE, Li Y, Chitambar CR, Logan B et al. Expression of MUM1/IRF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemia. Blood 2002; 100: 4671-4675.
18. Ding J, Komatsu H, Wakita A, Kato-Uranishi M, Ito M, Satoh A et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 2004; 103: 4198-4200.
19. Ohmori Y, Schreiber RD, Hamilton TA. Synergy between interferon-gamma and tumor necrosis factor-alpha in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor kappaB. J Biol Chem 1997; 272: 14899-14907.
20. Oikawa T, Yamada T. Molecular biology of the Ets family of transcription factors. Gene 2003; 303: 11-34.
21. Frank SR, Schroeder M, Fernandez P, Taubert S, Amati B. Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev 2001; 15: 2069-2082.
22. Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res 2003; 9: 3625-3634.
23. Kraft M, Riedel S, Maaser C, Kucharzik T, Steinbuechel A, Domschke W et al. IFN-gamma synergizes with TNF-alpha but not with viable. H pylori in up-regulating CXC chemokine secretion in gastric epithelial cells. Clin Exp Immunol 2001; 126: 474-481.
24. Hiroi M, Ohmori Y. The transcriptional coactivator CREB-binding protein cooperates with STAT1 and NF-kappa B for synergistic transcriptional activation of the CXC ligand 9/monokine induced by interferon-gamma gene. J Biol Chem 2003; 278: 651-660.
25. Piali L, Weber C, LaRosa G, Mackay CR, Springer TA, Clark-Lewis I et al. The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by the chemokines IP10 and Mig. Eur J Immunol 1998; 28: 961-972.
26. Hrdlickova R, Nehyba J, Bose Jr HR. Interferon regulatory factor 4 contributes to transformation of v-Rel-expressing fibroblasts. Mol Cell Biol 2001; 21: 6369-6386.
27. Jin YJ, Burakoff SJ, Bierer BE. Molecular cloning of a 25-kDa high affinity rapamycin binding protein, FKBP25. J Biol Chem 1992; 267: 10942-10945.
28. Mamane Y, Sharma S, Petropoulos L, Lin R, Hiscott J. Posttranslational regulation of IRF-4 activity by the immunophilin FKBP52. Immunity 2000; 12: 129-140.
29. Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 1997; 61: 246-257.
30. Farber JM. A macrophage mRNA selectively induced by gamma-interferon encodes a member of the platelet factor 4 family of cytokines. Proc Natl Acad Sci USA. 1990; 87: 5238-5242.
31. Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998; 101: 746-754.
32. Weng Y, Siciliano SJ, Waldburger KE, Sirotina-Meisher A, Staruch MJ, Daugherty BL et al. Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors. J Biol Chem 1998; 273: 18288-18291.
33. Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood 2000; 95: 627-632.
34. Trentin L, Agostini C, Facco M, Piazza F, Perin A, Siviero M et al. The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. J Clin Invest 1999; 104: 115-121.
35. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996; 184: 963-969.